

Form 1449 (Modified)

Atty Docket No.:
UCLAP013X1US
Applicant:
Fogelman et al
Filing Date
12/27/2004

Application No.:
10/520,207
Group
1654

**Information Disclosure
Statement By Applicant**

(Use Several Sheets if Necessary)

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	1	US A-4-643 988	2/17/1987	Segrest et al.			

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	2	EP 1186299 A1	3/13/2002	EP				
	3	WO 00 34469 A1	6/15/2000	WO				

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	4	“Apolipoprotein J ovarian tumour marker protein, SEQ ID NO: 60” XP002378357, DATABASE Geneseq [Online], February 8, 2002.
	5	“Human apolipoprotein A-IV fragment.” XP002378360, DATABASE Geneseq [Online], May 3, 1996.
	6	“Human apolipoprotein CIII, Apo CIII, immunogenic peptide 1-40.” XP002378358, DATABASE Geneseq [Online], December 4, 2001.
	7	“Human polypeptide SEQ ID NO: 14499.” XP002378359, DATABASE Geneseq [Online], November 6, 2001.
	8	JORDAN-STARCK TUAJUANDA C ET AL, “Mouse apolipoprotein J: Characterization of a gene implicated in atherosclerosis.” XP002378351, JOURNAL OF LIPID RESEARCH, vol. 35, pages 194-210, November 2, 1994.
	9	NAVAB MOHAMAD ET AL, “Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.” XP002378352, CIRCULATION, vol. 105, no.3, pages 290-292, January 22, 2002.
	10	SILKENSTEIN ET AL, “Identification of clusterin sequences mediating renal tubular cell interactions.” XP000851984, JOURNAL OF PEPTIDE RESEARCH, vol. 54, pages 449-457, 1999.
	11	Supplemental EP Search Report, Communication, May 24, 2006, 03746574.7-2107 PCT/US0309988.
	12	European Patent Office, Communication pursuant to Article 96(2) EPC, September 7, 2006, 03 746 574.7-2401.
	13	European Patent Office, Communication pursuant to Article 96(2) EPC, May 31, 2007, 03 746 574.7-2401.

Examiner

Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.